[csda] gadolinium-based contrast agent used with MRI or MR angiography (fwd)

[Guest guest]

_http://www.medpagetoday.com/Nephrology/GeneralNephrology/dh/4760_

(http://www.medpagetoday.com/Nephrology/GeneralNephrology/dh/4760)

The FDA updated a public health advisory today about a serious new kidney

disease that is apparently associated with a gadolinium-based contrast agent

used with MRI or MR angiography.

The agency said that as of Dec. 21 it had received reports of 90 patients

with moderate to end-stage kidney disease who developed the new disease, called

nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD),

after they had an MRI or MRA with a gadolinium-based contrast agent.

The FDA recommended that whenever possible patients with moderate to

end-stage kidney disease who need an imaging study, be given imaging methods

other

than MRI or MRA with a gadolinium-based contrast agent.